Aligos Therapeutics (ALGS) Net Cash Flow Growth (1y) (2020 - 2026)
Aligos Therapeutics (ALGS) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Aligos Therapeutics |
51.70 Mn |
-28.13 Mn |
- |
-68.07% |
| Date | Value |
|---|
| Mar 31, 2026 |
-68.07% |
| Dec 31, 2025 |
-1,519.15% |
| Sep 30, 2025 |
339.88% |
| Jun 30, 2025 |
-365.16% |
| Mar 31, 2025 |
133.00% |
| Dec 31, 2024 |
-97.45% |
| Sep 30, 2024 |
52.34% |
| Jun 30, 2024 |
76.08% |
| Mar 31, 2024 |
-4,551.65% |
| Dec 31, 2023 |
1,390.45% |
| Sep 30, 2023 |
-232.88% |
| Jun 30, 2023 |
133.79% |
| Mar 31, 2023 |
97.04% |
| Dec 31, 2022 |
90.53% |
| Sep 30, 2022 |
-70.83% |
| Jun 30, 2022 |
-167.14% |
| Mar 31, 2022 |
-303.79% |
| Dec 31, 2021 |
-128.32% |
| Sep 30, 2021 |
474.82% |
| Jun 30, 2021 |
-377.89% |
